C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells

Anne S. De Groot
University of Rhode Island, dr.annie.degroot@gmail.com

Ted M. Ross

See next page for additional authors

Follow this and additional works at: http://digitalcommons.uri.edu/immunology_facpubs

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use
This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our Terms of Use.

Citation/Publisher Attribution
De Groot, A. S., Ross, T. M., Levitz, L., Messitt, T. J., Tassone, R., Boyle, C. M., Vincelli, A. J., Moise, L., Martin, W., & Knopf, P. M. (2015). C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells. *Immunol Cell Bio*, 93(20), 189-197. Available at: http://www.nature.com/icb/journal/v93/n2/full/icb201489a.html

This Article is brought to you for free and open access by the Institute for Immunology and Informatics (iCubed) at DigitalCommons@URI. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells

Anne S. De Groot1,2, Ted M. Ross3, Lauren Levitz1, Timothy J. Messitt1, Ryan Tassone1, Christine M. Boyle1, Amber J. Vincelli1, Leonard Moise1,2, William Martin1, and Paul M. Knopf1

1EpiVax, Inc., 146 Clifford Street, Providence, RI, USA
2Institute for Immunology and Informatics, University of Rhode Island, 80 Washington Street, Providence, RI, USA
3Vaccine & Gene Therapy Institute of Florida, 9801 SW Discovery Way, Port Saint Lucie, FL, USA

Abstract

Complement fragment C3d covalently attached to antigens enhances immune responses, particularly for antigens lacking T cell epitopes. Enhancement has been attributed to receptor cross-linking between complement receptor CR2 (CD21) and polysaccharide antigen to surface IgM on naïve B cells. Paradoxically, C3d has still been shown to increase immune responses in CD21 KO mice, suggesting that an auxiliary activation pathway exists. In prior studies, we demonstrated the CD21-independent C3d adjuvant effect might be due to T cell recognition of C3d T helper epitopes processed and presented by MHC class II on the B cell surface. C3d peptide sequences containing concentrated clusters of putative human C3 T cell epitopes were identified using the epitope-mapping algorithm, EpiMatrix. These peptide sequences were synthesized and shown in vitro to bind multiple HLA-DR alleles with high affinity, and induce IFNγ responses in healthy donor PBMCs. In the present studies, we establish further correlations between HLA binding and HLA-specific lymphocyte reactions with select epitope clusters. Additionally, we show that the T cell phenotype of C3d-specific reactive T cells is CD4+CD45RO+ memory T cells. Finally, mutation of a single T cell epitope residing within the P28 peptide segment of C3d resulted in significantly diminished adjuvant activity in BALB/c mice. Collectively, these studies support the hypothesis that the paradoxical enhancement of immune responses by C3d in the absence of CD21 is due to internalization and processing of C3d into peptides that activate autoreactive CD4+ T helper cells in the context of HLA class II.
INTRODUCTION

Two methods of adjuvant conjugation to antigen have been shown to greatly improve the efficacy of polysaccharide vaccines: use of an immunogenic foreign T cell epitope-rich protein, and use of complement fragment C3d.\textsuperscript{1–3} The adjuvant effect of C3d is said to result from the synergistic effect of two events: (1) polysaccharide antigen binding to the IgM/D B cell receptor, and (2) C3d binding to the B cell complement receptor 2 (CR2 or CD21). The co-activation of these two signals has been shown to lower the threshold of activation and to promote a more robust immune response by inducing isotype switching, somatic hypermutation, and B cell memory generation.\textsuperscript{4} Yet in mice lacking complement receptors CR1 (CD35) and CR2 (CD21), immune responses to protein antigen-C3d conjugates were equally enhanced to the levels seen in wild-type mice.\textsuperscript{5–7} Further, C3−/− mice, but not CD21−/− have been shown to be deficient in T dependent responses.\textsuperscript{8} These findings suggest that the current model for C3d activity may be incomplete and an auxiliary immune activation pathway exists.

We have hypothesized that in addition to its molecular adjuvant property enhancing signal 1 in antigen-specific B cell activation, C3d also contains T cell epitopes that stimulate autoreactive C3d peptide-specific T helper cells, creating a response similar to that of any cognate T helper epitope.\textsuperscript{9} Multiple repeats of polysaccharide residues can cause cross-linking of antibody regions and internalization of the conjugate into the B cell antigen processing compartments. Processing and presentation of any protein components associated with the polysaccharide antigen that bind to MHC will ensue: the resulting peptide-associated MHC II complexes presented on the B cell surface generate help by activating CD4+ T cells via recognition of T cell antigen receptors. This induction of T-dependent (Td) responses may result in the generation of T cell help for any anti-polysaccharide B cell responses, generating higher antibody titers and higher affinity antibodies than T-independent (Ti) responses.

In previous studies, we used the EpiMatrix algorithm to identify T cell epitopes in complement C3 and assessed their binding potential to multiple HLA haplotypes.\textsuperscript{9} We determined that the frequency of putative T cell epitopes in complement C3 was greater than many other human plasma proteins analyzed using the EpiMatrix algorithm. Further, the distribution of these putative T helper epitopes within C3 was non-uniform and concentrated within the C3d segment. Thus, we have postulated that the previously-observed enhancement of the immune response by C3 might be due in part to the activation of C3d peptide-specific autoreactive T helper cells. This discovery of T cell epitopes within C3d offers a novel explanation for the adjuvant effect of C3d and a potential resolution of the paradoxical results observed in CD21 KO mice.

Here, we examine three putative T cell epitope “clusters” from C3d that were identified in earlier studies.\textsuperscript{9} In vitro HLA binding studies and ex vivo PBMC responses from four
separate HLA-typed donors correlated with epitope mapping predictions. Further, *ex vivo* PBMC responses to C3d peptides were found to be associated with a CD4+CD45RO+ population of memory T cells, suggesting that C3d-specific T cells are autoreactive memory T cells. Finally, the contribution of T cell epitope-mediated immunogenicity to C3d activity was confirmed by mutation of the single predicted T cell epitope in the P28 peptide segment of C3d expected to reduce binding to murine MHC. In immunization studies, T cell responses to hapten-conjugated C3d mutants were diminished, further supporting the contribution of autoreactive T helper responses to the adjuvant activity of the C3d fragment of C3.

**RESULTS**

**Epitope analysis and peptide synthesis**

Candidate T cell epitopes in C3 were identified using the EpiMatrix algorithm as described in Methods and reference 9. Within the 302-amino acid C3d sequence, 11 putative T cell epitope clusters with significant cluster scores were identified. Three peptides (aa 32–50, 100–118, and 190–209) were excluded from further study, as they had three of the four lowest cluster scores; two additional peptides (aa 73–96 and 176–198) were not selected for synthesis due to high hydrophobicity. The informatics analysis was repeated on the remaining six putative epitopes in 2010 with a revised version of the EpiMatrix algorithm, which had been retrained on a more robust set of epitopes using the expanded set of sequences available in 2009. This updated matrix is improved relative to the 2002 matrix and has demonstrated greater accuracy when benchmarked against other prediction tools. From the six putative epitopes previously identified, three peptides: C3d223–246, C3d248–265, and C3d269–286 were selected for further study based on their updated EpiMatrix scores, broad binding to a range of HLA in competition binding assays, and ability to induce IFNγ responses in non-HLA typed donors (see ref. 9 and Table 1). All three clusters are distributed in Region 2 (aa 175–290) of C3d; notably, C3d223–246 overlaps with the C3d peptide fragment P28 (aa 208–235), identified by Lambris et al., by 13 amino acids (Figure 1).

**HLA binding validates *in silico* predictions**

Class II HLA binding assays were conducted to validate the *in silico* EpiMatrix predictions, as described in Methods. Each of the C3d epitope peptides bound to at least one of the six different HLA DR alleles tested with high affinity (see Table 2). Peptide C3d223–246 bound with high affinity to four alleles (0101, 0401, 0701, 1101), moderate affinity to one allele (0301), and weak affinity to one allele (1501). Peptide C3d269–286 bound with high affinity to four alleles (0101, 0401, 0701, 1101) and weak affinity to two alleles (0301, 1501). Peptide C3d248–265 bound with high affinity to one allele (1101) and did not bind to the other five alleles tested. For greater than two-thirds of the peptide/HLA allele combinations, binding results confirmed EpiMatrix predictions (Table 2). Comparison of HLA binding results to our earlier work reveals some discrepancies with those found in current studies due to a number of modifications to the assay to improve robustness and sensitivity over time. This includes the use of peptides capped at their N- and C-termini to improve peptide stability, which likely contributed to improved binding affinity among predicted peptides.
that were non-binders in our earlier work (e.g., peptides C3d223–246 and C3d269–286 had high cluster scores but either did not bind or bound only weakly to 0101 and 0701 in the previous study, but both peptides had improved binding affinity to these alleles once capped). Furthermore, optimizations were introduced to increase signal-to-noise ratios; as a result, peptides that had previously bound weakly, possibly due to an initial high background producing a false positive signal (e.g. C3d248–265 binding with high affinity to 1501 in the previous work), exhibited weak or no detectable binding in the improved assay. Finally, the use of an updated, more accurate EpiMatrix algorithm in the current study led some peptides that were previously predicted to bind given HLA alleles to be re-classified as non-binders (e.g., C3d248–265 was originally predicted to bind 1501, but its updated EpiMatrix score classifies it as a non-binder for this allele, which corresponds to the negative binding results in vitro). Comparison of the results in this work to previous studies reveals improved correlations between in silico predictions and in vitro binding (83% correlation in this work vs. 50% correlation in earlier work), which we attribute to these assay improvements and use of the improved EpiMatrix algorithm.

**C3d epitopes induce IFNγ responses from multiple donors**

To confirm observations from HLA binding assays and correlate C3d-specific T cell responses to HLA background, we stimulated PBMCs from HLA-typed donors and tested for cytokine responses to C3d peptides by IFNγ ELISpot. PBMCs from four healthy donors were stimulated with a C3d peptide pool (comprised of C3d223–246, C3d248–265 and C3d269–286) or an irrelevant peptide (Pan-DR epitope; PADRE) for 10 days to expand the number of C3d-specific T cells from baseline. Harvested PBMCs were then re-stimulated with the C3d peptide pool, individual C3d peptides, PADRE, PHA (positive control), or no peptide. ELISpots were used to determine IFNγ secretion two days after re-stimulation. Each plot in Figure 2 shows IFNγ responses from one of four donors to each stimulation condition. As shown in Figure 2, most of the donors responded specifically to at least one C3d peptide, and all donors responded to the C3d peptide pool. No response was seen to these same peptides when donor cells were initially cultured with PADRE and then restimulated with C3d peptides. In most cases, ELSpot responses correlate well with EpiMatrix predictions and HLA binding. For example, Subject 666 (HLA DRB1*0701) responded strongly to C3d223–246 and C3d269–286 as predicted by EpiMatrix and as observed by HLA binding assay specifically for this donor’s HLA allotype (see Table 2, Figure 2A). Additionally, a response was observed for all three C3d peptides, including C3d248–265, for Subject 705. The HLA type of this donor (HLA DRB1*1101) matches the only allele predicted and observed by HLA binding assay specifically for this donor’s HLA allotype (see Table 2, Figure 2A). Subject 703, with HLA DRB1*0301 (Figure 2D), generated a low response to C3d223–246 and to the C3d peptide pool. Again, this result corresponds to the binding data; HLA DRB1*0301 only moderately bound C3d223–246, and only weakly bound or did not bind C3d269–286 and C3d248–265, respectively (Table 2). The only discordance observed with HLA binding was in Subject 706 (HLA DRB1*0401), who responded strongly to C3d223–246 as predicted and observed for HLA binding, but did not respond significantly to C3d269–286 (Table 2, Figure 2B).
Responses to C3d peptides are generated by CD4+ memory T cells in the periphery

In our previous work, we used immunophenotyping and fluorescence-activated cell sorting (FACS) to demonstrate that the IFN\(_\gamma\) response to C3d peptides was primarily generated by CD4+ cells. To extend this observation and confirm that C3d-specific CD4+ T cells also express cell surface markers characteristic of memory T cells (providing support for our hypothesis that C3d-specific memory T cells circulate in the periphery), we repeated the FACS assay with additional immunophenotyping to determine whether the C3d-specific response was due to naïve or memory T cells. A representative experiment is shown in Figure 3, in which PBMCs stimulated with a C3d peptide pool at a total concentration of 30 µg/ml or with MOG\(_{35-55}\) (negative control peptide) at 30 µg/ml were cultured for 10 days. Similar to C3d epitopes, MOG\(_{35-55}\) is an autologous T cell epitope that binds multiple HLA types. While MOG\(_{35-55}\) is an auto-antigen in multiple sclerosis, the peptide does not induce an immune response in healthy individuals. On day 10, PBMCs were stimulated with the C3d peptide pool, MOG\(_{35-55}\), the polyclonal stimulator CytoStim (Miltenyi), or media alone for three hours. After three hours of secondary stimulation, IFN\(_\gamma\)-positive cells were enriched using an IFN\(_\gamma\) secretion assay kit (Miltenyi), stained with antibodies for CD4, CD45RA (naïve marker) and CD45RO (memory marker), and analyzed by flow cytometry. We gated first on CD4+, IFN\(_\gamma\)+ cells and then on the CD45RA and CD45RO populations.

As shown in Figure 3, memory (CD4+IFN\(_\gamma\)+CD45RO+) T cells are the dominant population responding to the C3d peptides in this assay system. A mixed naïve (CD4+ IFN\(_\gamma\) +CD45RA+) and memory (CD4+IFN\(_\gamma\)+CD45RO+) response was generated to CytoStim, indicating naïve T cells could be re-stimulated under these conditions. This is in contrast to the negative control peptide, MOG\(_{35-55}\), which did not induce an autoreactive memory (or naïve) T cell response. These results suggest that T cell responses are specific to C3d, are not seen in response to other autologous peptides (in healthy control subjects), and are mediated by autoreactive memory T cells circulating in the periphery.

Disruption of the single T cell epitope in P28 diminishes the activity of C3d in vivo

It has been proposed that the adjuvant effect of C3d involves interaction between BCR:anti-polysaccharide and C3d:CD21, lowering the threshold of B cell activation by engaging CD19 with Igα/β. While the P28 peptide segment (amino acids 208–235of C3d) has previously been implicated as mediating C3d binding to CD21, this role has been disputed based on the 2011 crystal structure of C3d interacting with CD21. Rather, the finding that the P28 segment harbors a T cell epitope provides support for the reported adjuvant properties of P28, whether or not it is involved in mediating binding to CD21. The adjuvant activity of multiple copies of P28 has been established in the context of protein immunogens and DNA vaccine immunogens. Indeed, a 4X repeat of the P28 peptide segment retains equal adjuvant activity to a 3X repeat of full-length C3d when delivered as a recombinant DNA vaccine with the HIV-1 ENV\(_{gp120}\) glycoprotein. An EpiMatrix analysis of the P28 peptide segment revealed a single promiscuous HLA binding motif located at the C-terminus of P28 (Figure 4). Interestingly, this single T cell epitope overlaps with the N-terminal T cell epitope in the C3d\(_{223-246}\) epitope cluster described in this work, which is shown to bind multiple HLA alleles in vitro and to induce IFN\(_\gamma\) responses in multiple donors (Table 2, Figures 1 and 2). We hypothesized that if the adjuvant activity of P28 is
abolished or diminished due to mutation of this single T cell epitope, it would help explain the adjuvant activity of P28.

Using EpiMatrix, we selected two variants of the T cell epitope in the P28 peptide segment which were designed to disrupt HLA binding to eight of the most common HLA types (covering >90% of human populations) and mouse MHC alleles (Figure 4). The first modification (P28Mod1) was predicted to disrupt recognition by most HLA types and murine MHC alleles, and the second, more aggressive modification (P28Mod2) was predicted to fully disrupt recognition by all HLA types and murine MHC alleles. Amino acid modifications selected for each variant have been previously made and shown to have no effects on CD21 binding, effectively decoupling the impact of mutagenesis on epitope:MHC interactions from epitope:CD21 binding. Our group recently published work on the implementation of such methods to deimmunize Factor VIII (FVIII), in which we predicted and observed changes in immune responses to the modified FVIII epitopes for humanized mice and for FVIII-deficient mice.

In HLA binding assays, deimmunizing modifications to the peptide representing the specific region where the P28 peptide segment overlaps with C3d_223–237 reduced peptide binding to the DRB1*0101 and 0401 alleles in comparison with the corresponding wild type sequence (Table 3). These results suggest that the peptide mutations may also disrupt binding to mouse MHC and reduce antigenicity of P28.

A recombinant expression construct corresponding to the HIV-1 ENV_{gp120} glycoprotein antigen fused to a 4X repeat of P28 or “deimmunized” P28Mod1 or P28Mod2 was created for in vivo expression and analysis of adjuvant activity.

Six- to eight-week-old BALB/c mice received 5 µg of DNA by intramuscular gene gun delivery encoding ENV_{gp120}-4XP28, ENV_{gp120}-4XP28Mod1, and ENV_{gp120}-4XP28Mod2on weeks 0, 3, and 6. At week 8, blood was collected, and ENV_{gp120} titers were measured by enzyme-linked immunosorbent assay (ELISA). Figure 5 shows that while immunization with ENV_{gp120} glycoprotein recombinantly expressed with wild-type P28 contributed to robust immune responses as measured by anti-ENV_{gp120} antibody titers, immune responses to ENV_{gp120} were significantly diminished when recombinantly expressed with either of the P28 deimmunized modifications (P28Mod1 and P28Mod2). In fact, a further-diminished immune response was observed with P28Mod2, the more aggressive mutation predicted to more effectively disrupt recognition by both I-A^d and I-E^d. The results of this experiment suggest that the adjuvant activity of P28 may involve MHC binding and T cell epitope content, providing in vivo evidence for T cell mediated immunogenicity in the adjuvant activity of C3d.

**DISCUSSION**

Adjuvants consisting of a polysaccharide antigen covalently linked to either a foreign carrier protein or to complement component C3d often enhance the generation of a primary humoral response. The prevailing model suggests the adjuvant effect of C3d is due to B cell activation upon cross-linking of the antigen recognition molecules (Ig) and complement-
binding molecules (CD21), resulting in a lowered activation threshold and more robust immune response.4,15 Yet mice lacking complement receptors CD35 (CR1) and CD21 (CR2) were observed to respond to protein antigen-C3d conjugates in a similar or enhanced manner, respectively, as compared to wild-type mice6,7 These findings challenge the current models and suggest an auxiliary immune activation pathway. We thus propose a second component to the adjuvant effect of C3d: namely, that C3d is rich in T cell epitopes and that when, in the course of antigen internalization and processing, they are presented by MHC II to autoreactive T helper cells, this T cell help enhances antibody responses. In earlier work, we showed that C3d contains an unusually high concentration of T cell epitopes compared to other serum proteins, suggesting that T cell activation by MHC display of C3d epitopes may be an alternative mechanism for adjuvant activity of C3d.

In the present study, we provide evidence for the role of T cell epitope content and autoreactive T cells in the development of immune responses to C3d and associated antigens. Focusing on three peptides identified in our previous work,9 we establish that C3d epitope-specific responses (as judged by IFNγ ELISpot) are apparent in multiple donors and furthermore, donors respond to peptides in a manner consistent with HLA type as predicted by in silico methods and in vitro HLA binding assays (Table 2, Figure 2). The prior studies were conducted with non-HLA typed donors and HLA binding was performed with fewer alleles, preventing the correlations established in this work.

To further test the relative contribution of T cell epitopes to the adjuvant effect of C3d, we focused on the P28 peptide segment of C3d. P28 is an attractive candidate for deimmunization since it has a single T cell epitope (overlapping with the C3d223–246 epitope cluster identified in our studies) and has demonstrated adjuvant properties in the context of protein immunogens20 and DNA vaccine immunogens.5 By mutating this single T cell epitope, we effectively demonstrate the importance of T cell epitope content to the adjuvant activity of C3d. Our finding that targeted mutations to P28, predicted to disrupt MHC recognition (Figure 4) and significantly decreasing the adjuvant activity of P28 in vivo (Figure 5), supports the role that T cell epitope content may have in C3d adjuvant activity.

Regions of C3d encompassing predicted T cell epitopes appear to be highly conserved throughout evolution of multicellular phyla - further highlighting their critical biological function (Matthew Ardito, personal communication). A better understanding of the biological role of these epitopes as undertaken in this study and careful evolutionary mapping may place C3d at a critical evolutionary junction where humoral immunity meets cellular responses. In fact, components of complement have been shown to be expressed by dendritic cells (critical for cellular immunity) and have further been shown to be necessary for T cell activation.22,23 We believe this activation to be in part due to MHC presentation of C3d epitopes.

Focusing on the T cells responding to these epitopes, immunophenotyping of the C3d epitope-activated T cells points to a prominent role for CD4+CD45RO+ memory T cells circulating in the periphery in this response (Figure 3). Thus it appears that C3d-specific autoreactive T cells are circulating in the periphery, poised to respond to C3d associated with foreign antigens. While there are numerous examples of unwanted responses by
autoreactive T cells in such autoimmune diseases as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, these data suggest a natural, beneficial role for autoreactive T cells. A link between activation of complement and antibody-associated autoimmune disorders such as uveoretinitis and Systemic Lupus Erythematosus has been described. Additionally, it is known that thymic deletion of autoreactive T cells is imperfect; 25–40% of autoreactive T cells escape into the periphery because of low TCR avidity, absence of antigen expression in the thymus, inefficient expression, or inefficient processing. This escape of autoreactive T cells to the periphery may indicate a need for them in natural immunity.

We have used our immunoinformatics tools to identify other T cell epitopes in autologous proteins that suppress immune response. Using EpiMatrix and ClustiMer, we discovered regulatory T cell epitopes (Tregitopes) that reside within IgG and likely within other autologous, high-abundance serum proteins, pointing to a very different role for Tregitope-autoreactive T cells -- in this instance, induction of natural Tregs and tolerance to associated antigenic epitopes. Tregitopes may serve to dampen immune response to co-administered immunogens (such as antibody idiotypes). In contrast to Tregitopes, which may serve as a universal “off switch,” our data would indicate that C3d induces an effector response to associated epitopes, acting as a universal “on switch.”

A better understanding of the C3d-specific T cell responses observed here may lead to an enhanced knowledge of the role of complement in autoimmune disorders, as well as the role of autoreactive T cells in autoimmune disease and natural defense mechanisms. Our findings are consistent with the existence of a CD21-independent pathway by which peripheral T helper cells are activated by self peptide-MHC II complexes, aiding in the adjuvant effect of C3d opsonization, and perhaps representing a critical link between humoral and cellular responses to foreign antigens.

**MATERIALS AND METHODS**

**Immunoinformatics**

T cell epitopes in human C3d were identified using the epitope-mapping algorithm EpiMatrix. Updated cluster scores are referenced in this work. The 302-amino-acid sequence was parsed into overlapping 9-mer frames, each of which was analyzed against a panel of eight common HLA class II alleles that cover >90% of human populations (DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301, and DRB1*1501). From this EpiMatrix analysis, 11 “clusters,” or regions of high putative T cell epitope content, were identified, of which three candidates (17–23 amino acids in length) were chosen for synthesis. In-depth discussion of the methods used for making predictions with EpiMatrix can be found in De Groot et al. Frames are given Z-scores, which range from approximately −3 to +3 and are normally distributed. These scores indicate the potential of a 9-mer frame to bind to a given HLA allele. Frames containing four or more alleles scoring above 1.64 are referred to as EpiBars, and have an increased likelihood of binding to HLA. Significant EpiMatrix scores across multiple frames are then aggregated to create an EpiMatrix Cluster Immunogenicity score. Epitope clusters
identified in reference 9 using EpiMatrix version 1.1 were re-analyzed in the updated version 1.2. Updated cluster scores are referenced for this work in Table 1.

Peptide synthesis

Peptide synthesis was conducted (21st Century Biochemicals; Marlboro, MA, USA) using solidphase peptide synthesis employing N-(9-fluoronylmethoxycarbonyl) (Fmoc)-based chemistry and Fmoc-L-amino acid building blocks on an automated Rainin Symphony-Protein Technologies synthesizer to >80% purity. Peptides were synthesized with the amino and carboxyl ends blocked to reduce peptide degradation during incubations. Peptide sequence and purity was confirmed by MALDI/TOF MS on a QSTAR XL Pro mass spectrometer. The peptides selected for this study (located at amino acids 223–246, 248–265, and 269–286 of the C3d sequence) were based on EpiMatrix analyses described above (see Table 1).

HLA binding assays

Each of the three C3d peptides was tested in HLA binding assays to six alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, and DRB1*1501. Class II HLA binding assays were adapted for high throughput by EpiVax from methods previously described by Kwok and colleagues.36 Non-biotinylated test peptide over a range of concentrations (2–128 µM) competed against a biotinylated tracer peptide (0.1–1 µM) for binding to purified class II HLA molecules (0.5–2 µg/ml) in 96-well plates at 37°C for 24 hours. Pan anti-class II antibodies (L243, anti-HLA-DR) were used to capture class II complexes on ELISA plates, which were developed using streptavidin-europium and read on a time-resolved fluorescence plate reader. Nonlinear regression analysis was performed, and half maximal inhibitory concentrations (IC50) values were calculated.

Blood samples

Interferon gamma ELISpot assays were performed using cryopreserved peripheral blood mononuclear cells (PBMCs) separated by Ficoll density gradient centrifugation of whole blood. Healthy human subjects were recruited from Clinical Partners in Johnston, RI, USA in accordance with all federal guidelines and institutional policies. Institutional review boards in Providence, RI approved the informed consent procedures and research protocols. Informed consent was obtained prior to obtaining all samples for this study.

ELISpot assays

Cryopreserved PBMCs from four healthy human donors with HLA types DRB1*0301, DRB1*0401, DRB1*0701, and DRB1*1101 were used to determine the frequency of epitope-specific T lymphocytes. Purified PBMCs were stimulated on day 1 with either pan HLA DR-binding epitope (PADRE) or a pool of three C3d-derived peptides at a final total peptide concentration of 30 µg/ml in RPMI 1640+GlutaMax (Life Technologies; Grand Island, NY, USA) supplemented with 10% human AB serum (Valley Biomedical; Winchester, VA, USA), 1% L-glutamine (Life Technologies), 1% 1M HEPES (Life Technologies), and 50 µg/ml Gentamycin (Sigma-Aldrich; St. Louis, MO, USA). Cells were plated at 5 million cells per well in a 12-well plate and incubated for 10 days at 37°C and
5% CO₂. IL-2 (10 ng/ml) and IL-7 (20 U/ml), both manufactured by BioSource (Nivelles, Belgium), were added to each of the wells on days 1 and 5 of the incubation period, and a half-medium exchange was performed on day 5. On day 10, PBMCs were harvested and added at 2.5 × 10⁵ cells per well to a Mabtech® IFNγ ELISpot plate pre-coated with anti-IFNγ antibody (Mabtech; Nacka, Sweden). Cells were re-stimulated in triplicate in the ELISpot plate with 10 µg/ml of one of the three individual C3d peptides, 30 µg/ml of PADRE, 30 µg/ml of the C3d peptide pool, or 2 µg/ml PHA (positive control). Twelve wells of cells without re-stimulation were used to measure assay background. Plates were incubated at 37°C and 5% CO₂ for 48 hours and were developed according to the manufacturer’s instructions. To develop, plates were washed and biotinylated anti-IFNγ was added; after a two hour incubation, plates were washed again, and streptavidin-HRP was added. Plates were incubated for one hour, washed, and developed by addition of TMB substrate. The frequency of antigen-specific cells was calculated as the number of spots per 10⁶ cells seeded. Responses were considered positive if the number of spots was significantly greater by Student’s t-test than 50 spot forming cells per well (1 spot over background per 20,000 PBMCs).

Immunophenotyping

PBMCs from a single DRB1*0701-positive donor (Clinical Partners; Johnston, RI, USA) were stimulated with a C3d peptide pool (comprised of C3d_{223–246}, C3d_{248–265}, and C3d_{269–286}) at 30 µg/ml or with MOG_{35–55} peptide at 30 µg/ml for 10 days under the same conditions as the ELISpot preculture. On day 10, PBMCs were stimulated with the C3d peptide pool, MOG_{35–55}, CytoStim (Miltenyi Biotec; Bergisch Gladbach, Germany), or media alone for three hours. After secondary stimulation, IFNγ-positive cells were enriched using an IFNγ secretion assay kit (Miltenyi) and then co-stained with anti-human antibodies for CD4-FITC, CD45RA-PerCP, and CD45RO-APC, according to the manufacturer’s recommendations (eBioscience; San Diego, CA, USA). Samples were acquired on a Beckton Dickinson FACSCalibur flow cytometer. In FlowJo analysis software, CD4+, IFNγ+ cells were identified from the live lymphocytes, and proportions of CD45RA+ and CD45RO+ cells were examined within this double-positive population.

Mouse studies

BALB/c mice (*Mus musculus*, female, 6–8 weeks) were purchased from Harlan Sprague Dawley (Indianapolis, IN, USA), housed in microisolator units with free access to food and water, and cared for under USDA guidelines for laboratory animals. Mice (n=5 per group) were gene gun-immunized on shaved abdominal skin using the hand-held Bio-Radgene delivery system. Mice were immunized with two gene gun doses (at weeks 0, 3 and 6) containing 5 µg of DNA (encoding ENV_{gp120-4xP28}, ENV_{gp120-4xP28Mod1}, or ENV_{gp120-4xP28Mod2}) per 0.5 mg of approximately 1 µm gold beads (Bio-Rad; Hercules, CA, USA) at a helium pressure setting of 400 lb/in². Fourteen days after the third vaccination (week 8), blood was collected from anesthetized mice via the retro-orbital plexus and transferred to a microfuge tube. For blood sample collection, animals were anesthetized with a mixture of ketamine/xylazine. Tubes were centrifuged, and sera was removed and frozen at −20 ± 5°C. ENV_{gp120} antibody titers were measured by ELISA. P28Mod1 alone was used as a negative control, and codon optimized gp120 (cogp120),
which expresses 7–10 times more gp120 protein than wtgp120 at the same DNA dose\textsuperscript{37}, was used as a positive control. For data processing, the single highest responding mouse in every group was removed from analysis. All procedures were in accordance with the NRC Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, and the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories.

**ELISA**

The ELISA was used to assess total antibody titer to the HIV-1 envelope. High-binding, 96-well polystyrene plates (Costar; Lowell, MA, USA) were coated overnight with 50 ng/well of recombinant ENV. Plates were blocked with 5% milk diluted in PBS with 0.05% Tween 20. Serum samples were diluted in blocking buffer and added to plates. Serum was two-fold serially diluted and allowed to incubate for 1 hour at room temperature. Plates were washed, and horseradish peroxidase (HRP)-linked species-specific antibody against IgG was diluted in blocking buffer and added to plates. Plates were incubated for 1 hour at room temperature. Plates were washed, and HRP was developed with TMB substrate (Sigma-Aldrich). Plates were incubated in the dark for 15 minutes, and then the reaction was stopped with 2N H\textsubscript{2}SO\textsubscript{4}. Optical densities at a wavelength of 450nm (OD\textsubscript{450}) were read by a spectrophotometer (BioTek; Winooski, VT, USA), and endpoint dilution titers were determined as the reciprocal dilution of the last well which had an OD\textsubscript{450} above the mean OD\textsubscript{450} plus two standard deviations of naïve animal sera.

**ACKNOWLEDGMENTS**

This work was supported by funding under the NIH U19AI082642 Translational Immunology Research and Accelerated [vaccine] Development (TRIAD) pilot grant. The authors would also like to thank Leslie Cousens for expert advice regarding immunophenotyping experiments, Frances Terry for initial T cell epitope mapping of P28, and Elizabeth McClaine for project management contributions.

**REFERENCES**

1. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated bacteria—new potentials for conjugate vaccines? Scand J Immunol. 2003; 58:119–128. [PubMed: 12869132]
2. Mitsuyoshi JK, Hu Y, Test ST. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide. Infect Immun. 2005; 73:7311–7316. [PubMed: 16239528]
3. Test ST, Mitsuyoshi J, Connolly CC, Lucas AH. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun. 2001; 69:3031–3040. [PubMed: 11292721]
4. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science. 1996; 271:348–350. [PubMed: 8553069]
5. Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv. Exp. Med. Biol. 2006; 586:249–264. Adv Exp Med Biol 2006; \textbf{586}; 249–264. [PubMed: 16893077]
6. Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, et al. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol. 2005; 175:8011–8023. [PubMed: 16339538]
7. Haas KM, Toapanta FR, Oliver JA, Poe JC, Weis JH, Karp DR, et al. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol. 2004; 172:5833–5837. [PubMed: 15128761]

8. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med. 2002; 8:373–378. [PubMed: 11927943]

9. Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, De Groot AS. Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol. 2008; 86:221–225. [PubMed: 18180801]

10. De Groot, AS.; Cohen, T.; Ardito, M.; Moise, L.; Martin, B.; Berzofsky, JA. Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. In: Kaufmann, S.; Kabelitz, D., editors. Methods in Microbiology: Immunology of Infection. Burlington, MA: Academic Press; 2010. p. 35-66.

11. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol. 2009 May; 131(2):189–201. [PubMed: 19269256]

12. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol. 2007 Jul; 124(1):26–32. [PubMed: 17490912]

13. Lambris JD, Ganu VS, Hirani S, Muller-Eberhard HJ. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A. 1985; 82:4235–4239. [PubMed: 2408276]

14. Kerlero de Rosbo N, Mendel I, Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur J Immunol. 1995; 25:985–993. [PubMed: 7737302]

15. Luxembourg AT, Cooper NR. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J Immunol. 1994; 153:4444–4457. [PubMed: 7525704]

16. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol. 2000 Jan;18:393–422. [PubMed: 10837064]

17. Servis C, Lambris JD. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. J Immunol. 1989; 142:2207–2212. [PubMed: 2784456]

18. Diefenbach RJ, Isenman DE. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2. J Immunol. 1995; 154:2303–2320. [PubMed: 7868901]

19. Van den Elen JMH, Isenman DE. A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science. 2011; 332:608–611. [PubMed: 21527715]

20. Lou D, Kohler H. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol. 1998; 16:458–462. [PubMed: 9592395]

21. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope demunization of Factor VIII in vitro and in vivo. Clin Immunol. 2012 Mar; 142(3):320–331. Epub 2011 Dec 8. [PubMed: 22222093]

22. Li K, Fazekasova H, Wang N, Sagoo P, Peng Q, Khamri W, Gomes C, et al. Expression of complement components, receptors and regulators by human dendritic cells. Mol Immunol. 2011; 48:1121–1127. [PubMed: 21397947]

23. Peng Q, Li K, Patel H, Sacks SH, Zhou W. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol. 2006; 176:3330–3341. [PubMed: 16517700]

24. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev. 2008; 7:550–557. [PubMed: 18625444]

25. VanderBorght A, Geusens P, Raus J, Stinissen P. The autoimmune pathogenesis of rheumatoid arthritis: role of auto-reactive T cells and new immunotherapies. Semin Arthritis Rheum. 2001; 31:160–175. [PubMed: 11740797]
26. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007; 8:913–919. [PubMed: 17712344]

27. Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum. 2010; 62:837–844. [PubMed: 20187154]

28. Chen M, Muckersie E, Luo C, Forrester JV, Xu H. Inhibition of the alternative pathway of complement activation reduces inflammation in experimental autoimmune uveoretinitis. Eur J Immunol. 2010; 40:2870–2881. [PubMed: 20806290]

29. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 1995; 3:407–415. [PubMed: 7584132]

30. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity. 2000; 13:829–840. [PubMed: 11163198]

31. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol. 2004; 4:688–698. [PubMed: 15343368]

32. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood. 2008; 112:3303–3311. [PubMed: 18660382]

33. De Groot, AS.; Rayner, J.; Martin, W. Modeling the immunogenicity of therapeutic proteins using T cell epitope mapping. In: Brown, F.; Mire-Suis, AR., editors. Immunogenicity of Therapeutic Biological Products: Developments in Biologicals. Vol. 112. Basel: Karger; 2003. p. 71-80.

34. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998; 160:3363–3373. [PubMed: 9531296]

35. De Groot AS, Ardito M, Moise L, Gustafson EA, Spero D, Tejada G, et al. Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine. Immunome Res. 2011; 7:7.

36. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Neporn GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006; 203:961–971. [PubMed: 16585267]

37. Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol. 2004 May; 78(9):4710–4719. [PubMed: 15078953]
| P28 (C3d<sub>208-235</sub>) | C3d<sub>223-246</sub> |
|---------------------------|-------------------------|
| KFLTTAKDKN{RED}WEDP{RED}GKQLYNVEATSYA | GKQLYNVEATSYA{BLUE}AL{BLUE}ALL{BLUE}QLKDFD |

**Figure 1. The T cell epitope region of C3d residues 223–246 overlaps with P28**

The T cell epitope shared between P28 and C3d<sub>223-246</sub> is shown in bold. Amino acids in italics and underlined were mutated. Solid underline denotes amino acids mutated to alanine in P28Mod1. The additional K>N mutation in P28Mod2 is denoted by the dotted underline. The P28 region, which contains the major binding site of C3d to CD21<sup>13</sup> shares 13 amino acids with C3d.
Figure 2. PBMCs from healthy donors respond specifically to C3d epitope clusters

Frozen PBMC samples from four healthy donors (A–D) were thawed and stimulated for 10 days with either a pool of human C3d epitope peptides or a non-specific control peptide, PADRE. Cells were re-stimulated in a 48-hour IFNγ ELISpot with either individual peptides or pools. A response was considered positive if the number of spots was greater than or equal to 50 spot forming cells over background per 10⁶ PBMCs. HLA type of donors is...
shown at the top of each graph. PBMCs from all donors responded to C3d peptides when cultured with the C3d peptide pool.
Figure 3. C3d epitopes specifically induce a memory T cell response
Primary stimulations were performed as in Figure 2. Secondary stimulations with media, C3d peptide pool, MOG35-55 or CytoStim (Miltenyi) were performed for three hours. IFNγ-secreting cells were then captured, magnetically separated (Miltenyi) and labeled with antibodies for CD4, CD45RA (naive marker) and CD45RO (memory marker). Cells were first gated for CD4+IFNγ+, then CD45RA and CD45RO. Each primary stimulation group above is subtracted for background with secondary stimulation of media alone. Incubation and re-stimulation with the C3d peptide pool produced a significant increase in the CD4+IFNγ+CD45RO+ memory T cell subpopulation.
Figure 4. Targeted mutation of the single T cell epitope in P28 abolishes predicted binding to HLA and MHC alleles

EpiMatrix cluster reports show the P28, P28Mod1 and P28Mod2 sequences parsed into overlapping 9-mer frames. Each 9-mer is analyzed for predicted recognition by eight common HLA haplotypes and MHC alleles I-A<sub>b</sub>, I-A<sub>d</sub> and I-E<sub>d</sub>. Z-Scores above 1.64 are predicted to bind respective alleles. Epitope/HLA matches are shown in shaded boxes. Modified amino acids in P28Mod1 and P28Mod2 are underlined. The P28Mod1 variant is predicted to disrupt binding to most MHC alleles, and the more aggressive P28Mod2 variant is predicted to fully disrupt binding.

| Frame | AA Sequence | DRB1*0101 Z-Score | DRB1*0301 Z-Score | DRB1*0401 Z-Score | DRB1*0701 Z-Score | DRB1*0801 Z-Score | DRB1*1101 Z-Score | DRB1*1301 Z-Score | DRB1*1501 Z-Score | I-A<sub>b</sub> Z-Score | I-A<sub>d</sub> Z-Score | I-E<sub>d</sub> Z-Score | Hit Count |
|-------|-------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|-----------------|-----------------|-----------------|-----------|
| 1     | KFTTAKKKK   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 2     | FLTTAKKKN   | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 3     | LT7TAKKKN   | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17            | 0.17            | 0.17            | 0.17      |
|       |             |                    |                    |                    |                    |                    |                    |                    |                    |                 |                 |                 |           |
| 17    | FLYNVEAT    | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 18    | QLYNVEAT    | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 19    | LVYNEATSYS  | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 20    | YNVEATSYS   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |

| Frame | AA Sequence | DRB1*0101 Z-Score | DRB1*0301 Z-Score | DRB1*0401 Z-Score | DRB1*0701 Z-Score | DRB1*0801 Z-Score | DRB1*1101 Z-Score | DRB1*1301 Z-Score | DRB1*1501 Z-Score | I-A<sub>b</sub> Z-Score | I-A<sub>d</sub> Z-Score | I-E<sub>d</sub> Z-Score | Hit Count |
|-------|-------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|-----------------|-----------------|-----------------|-----------|
|       |             |                    |                    |                    |                    |                    |                    |                    |                  |                 |                 |             |
| 1     | KFTTAKKKK   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 2     | FLTTAKKKN   | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 3     | LT7TAKKKN   | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17            | 0.17            | 0.17            | 0.17      |
|       |             |                    |                    |                    |                    |                    |                    |                    |                    |                 |                 |                 |           |
| 17    | FLYNVEAT    | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 18    | QLYNVEAT    | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 19    | LVYNEATSYS  | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 20    | YNVEATSYS   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |

| Frame | AA Sequence | DRB1*0101 Z-Score | DRB1*0301 Z-Score | DRB1*0401 Z-Score | DRB1*0701 Z-Score | DRB1*0801 Z-Score | DRB1*1101 Z-Score | DRB1*1301 Z-Score | DRB1*1501 Z-Score | I-A<sub>b</sub> Z-Score | I-A<sub>d</sub> Z-Score | I-E<sub>d</sub> Z-Score | Hit Count |
|-------|-------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|-----------------|-----------------|-----------------|-----------|
|       |             |                    |                    |                    |                    |                    |                    |                    |                  |                 |                 |             |
| 1     | KFTTAKKKK   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 2     | FLTTAKKKN   | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 3     | LT7TAKKKN   | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17               | 0.17            | 0.17            | 0.17            | 0.17      |
|       |             |                    |                    |                    |                    |                    |                    |                    |                    |                 |                 |                 |           |
| 17    | FLYNVEAT    | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 18    | QLYNVEAT    | 0.56               | 0.54               | 0.54               | 0.58               | 0.54               | 0.54               | 0.58               | 0.54               | 0.58            | 0.58            | 0.58            | 0.58      |
| 19    | LVYNEATSYS  | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
| 20    | YNVEATSYS   | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00               | 1.00            | 1.00            | 1.00            | 1.00      |
Figure 5. Mutation of the single T cell epitope in P28 significantly diminishes its adjuvant activity

The immunogenicity of wild-type gp120 (wtgp120; open circles) is enhanced when conjugated to a 4X concatamer of P28 (wtgp120-p28; black circles) as measured by anti-Env titers. When conjugated to a 4X concatamer of P28 mutated at the single predicted T cell epitope (wtgp120-p28mod1, wtgp120-p28mod2; open squares and black squares, respectively) the adjuvant activity of P28 is significantly diminished. P28mod1 alone was used as a negative control. Codon optimized gp120 (cogp120), which expresses 7–10 times more gp120 protein than wtgp120 at the same DNA dose37, was used as a positive control.
Immunization with ENVgp120 glycoprotein conjugated to p28mod1 or p28mod2 significantly diminished antibody responses.
Table 1
C3d peptide locations, sequences, and cluster scores

Amino acids were numbered according to their position within C3d (N terminus to C terminus); position 1 of C3d corresponds to position 1002 of C3. EpiMatrix cluster scores are a measure of epitope promiscuity (probability to be recognized by multiple HLA alleles). Potentially immunogenic epitopes tend to have higher EpiMatrix cluster scores.

| Peptide name | Start and stop in mature C3d | Equivalent start and stop in C3 | Sequence | EpiMatrix cluster score |
|---------------|-------------------------------|---------------------------------|---------------------------------|-------------------------|
| C3d223–246    | 223–246                       | 1224–1247                       | GKQLYNVEATSYALLALLQLKDFD        | 7.12                    |
| C3d248–265    | 248–265                       | 1249–1266                       | VPPVVRWLNEQRYYGGGY              | 6.24                    |
| C3d269–286    | 269–286                       | 1270–1287                       | QATFVFQALAQYQKDAP              | 23.01                   |
Table 2
EpiMatrix predictions correlate well with *in vitro* HLA binding

Peptides were predicted to bind a given HLA allele if their EpiMatrix Z-score was >1.64. Binding results that differ from predicted results are in parenthesis. Binding results confirmed EpiMatrix predictions for 83% of the peptide/HLA allele combinations.

| Peptide name | HLA-DRB1 Allele | EpiMatrix Z-score | Prediction | Binding IC₅₀ (µM) |
|--------------|-----------------|------------------|------------|-----------------|
| C3d233–246   |                 |                  |            |                 |
| 0101         | 0101            | 1.75             | binder     | <2              |
| 0301         | 0301            | 1.65             | binder     | 13.96           |
| 0401         | 0401            | 2.37             | binder     | <2              |
| 0701         | 0701            | 1.62             | non-binder | (<2)            |
| 1101         | 1101            | 1.96             | binder     | <2              |
| 1501         | 1501            | 1.92             | binder     | 85.07           |
| C3d248–265   |                 |                  |            |                 |
| 0101         | 0101            | 1.90             | binder     | (non-binder)    |
| 0301         | 0301            | 1.80             | binder     | (non-binder)    |
| 0401         | 0401            | 1.63             | non-binder | non-binder      |
| 0701         | 0701            | 0.72             | non-binder | non-binder      |
| 1101         | 1101            | 2.28             | binder     | <2              |
| 1501         | 1501            | 1.35             | non-binder | non-binder      |
| C3d269–288   |                 |                  |            |                 |
| 0101         | 0101            | 1.69             | binder     | 5.63            |
| 0301         | 0301            | 1.72             | binder     | 77.63           |
| 0401         | 0401            | 2.68             | binder     | 9.64            |
| 0701         | 0701            | 1.70             | binder     | 2.45            |
| 1101         | 1101            | 2.37             | binder     | <2              |
| 1501         | 1501            | 2.43             | binder     | >100            |
Table 3

HLA binding of the single T cell epitope in P28 and its deimmunized variants

HLA binding was assessed for the sequence overlapping the P28 peptide segment and C3d\textsubscript{223–237} (Figure 1) and two variants designed to disrupt binding. Assays were performed for HLA alleles predicted to bind the wild type sequence. Modified amino acids in peptide sequences are underlined and in bold. Binding affinities are expressed as IC\textsubscript{50} values in nM. The variant (MOD1 and MOD2) mutations reduced peptide binding to HLA DRB*0101 and *0401, as indicated by higher IC\textsubscript{50} values.

| Peptide Sequence, C3d\textsubscript{223–237} | Binding IC\textsubscript{50} Values (nM) by HLA Allele |
|-------------------------------------------|-----------------------------------------------|
|                                          | DRB1*01:01     | DRB1*03:01     | DRB1*04:01     |
| WT: GKQLYNVEATSYALL                      | 365            | 2396           | 170            |
| MOD1: GKQ\textsubscript{AA}NVEATSYALL    | 582            | 2873           | 5202           |
| MOD2: GN\textsubscript{AA}NVEATSYALL     | 992            | 1208           | 4407           |

Immunol Cell Biol. Author manuscript; available in PMC 2015 August 01.